Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a diabetes drug help detect Alzheimer's early?

NCT ID NCT03560960

Diagnosis Sponsor: Boston University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study tests whether a single injection of pramlintide, a diabetes drug, can temporarily increase levels of Alzheimer's-related proteins in the blood, potentially revealing early signs of the disease. Researchers will measure changes in beta-amyloid and tau proteins before and after injection in 57 people with mild cognitive impairment, Alzheimer's, or normal cognition. The goal is to develop a simple, accessible blood test for early Alzheimer's detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pramlintide (Symlin)
What this could lead to
If successful, this could lead to a simple blood test for early Alzheimer's detection, helping diagnose the disease before severe symptoms appear.
What could go wrong
This is a very early, small study (57 people) testing a biomarker, not a treatment. The approach may not reliably distinguish early Alzheimer's from other conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

57 people

The number who actually took part.

Started

Feb 2020

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current research subjects at the BU , Memory Center VA Boston Healthcare, or Indiana University Alzheimer Disease Center * A consensus diagnosis of probable Alzheimer's Disease (AD), amnestic mild cognitive impairment (MCI), or control * BMI of 20-35 * Probable AD subjects must be confirmed for positive AD pathology in the central nervous center (CNS0 * Probable AD subjects must have a designated research proxy signed before they became demented. Exclusion Criteria: * Diabetes mellitus * Gastroparesis * Use of insulin, pramlintide, other injectable anti-hyperglycemic agents, such as glucagon like peptide-1 (GLP-1), or oral anti-diabetic products * Unexplained hypoglycemia (glucose ≤ 60 mg/dL) or hyperglycemia (glucose ≥ 126 mg/dL) pre-injection * History of stroke * Seizures or use of anti-seizure medications * History of brain injury and loss of consciousness * Diagnosed cerebral amyloid angiopathy (CAA) * Infection within 1 month

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Mild cognitive impairment

Contacts and locations

Locations

  • BU Alzheimer Disease Center

    Boston, Massachusetts, 02118, United States

  • Indiana University Alzheimer Disease Center

    Indianapolis, Indiana, 46202, United States

  • Memory Center VA Boston Healthcare

    Jamaica Plain, Massachusetts, 02130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.